<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03364023</url>
  </required_header>
  <id_info>
    <org_study_id>MDT16066SOLSEA</org_study_id>
    <nct_id>NCT03364023</nct_id>
  </id_info>
  <brief_title>Post-Market Registry Of Stroke Patients Treated With Medtronic Neuro Thrombectomy Devices to Collect Real World Data in South East Asia</brief_title>
  <acronym>PROSPR-SEA</acronym>
  <official_title>Post-Market Registry Of Stroke Patients Treated With Medtronic Neuro Thrombectomy Devices to Collect Real World Data in South East Asia (PROSPR-SEA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Neurovascular Clinical Affairs</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Neurovascular Clinical Affairs</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this post-market registry is to collect real-world data associated with the&#xD;
      use of Medtronic market-released neurothrombectomy devices in acute ischemic stroke (AIS)&#xD;
      patients from countries in South East Asia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, non-randomized, observational registry designed to&#xD;
      collect real world data associated with the use of Medtronic market-released&#xD;
      neurothrombectomy devices in acute ischemic stroke (AIS) patients from countries in South&#xD;
      East Asia, including Singapore, Thailand and Vietnam. The primary objective of this registry&#xD;
      is to assess clinical outcomes associated with the use of these devices in patients&#xD;
      experiencing AIS due to large intracranial vessel occlusion within 8 hours of symptom onset.&#xD;
      This registry may enroll up to 500 patients.&#xD;
&#xD;
      This clinical trial information was submitted voluntarily under the applicable law and,&#xD;
      therefore, certain submission deadlines may not apply. (That is, clinical trial information&#xD;
      for this applicable clinical trial was submitted under section 402 (j)(4)(A) of the Public&#xD;
      Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by&#xD;
      sections 402 (j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">July 2, 2019</completion_date>
  <primary_completion_date type="Actual">July 2, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin Scale (mRS) at 90 Days</measure>
    <time_frame>90 Days Post Procedure</time_frame>
    <description>mRS is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke.&#xD;
0 No symptoms at all&#xD;
No significant disability despite symptoms; able to carry out all usual duties and activities&#xD;
Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance&#xD;
Moderate disability; requiring some help, but able to walk without assistance&#xD;
Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance&#xD;
Severe disability; bedridden, incontinent and requiring constant nursing care and attention&#xD;
Dead</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Symptomatic Intracranial Hemorrhage (sICH) at 24 Hrs ± 8 Hrs Post Procedure</measure>
    <time_frame>24 hrs ± 8 hrs post procedure</time_frame>
    <description>Number of participants with symptomatic Intracranial hemorrhage (sICH) is defined as &gt;/= 4 points worsening from baseline on the National Institutes of Health Stroke Scale (NIHSS) associated with an image finding of intra-cranial hemorrhage (i.e., intracerebral or intraventricular) at 24 +/- 8 hrs post procedure.&#xD;
The NIHSS is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. NIHSS scores range from 0 - 42. A score of 0 indicates no stroke symptoms. Higher scores indicate incremental levels of neurological impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-Cause Mortality Through 90 Days Post Procedure</measure>
    <time_frame>90 Days Post Procedure</time_frame>
    <description>Death through 90 days post procedure classified as neurological or non-neurological, with event leading to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Emboli in New Territory (ENT) at 24 Hrs ± 8 Hrs Post Procedure</measure>
    <time_frame>24 hrs ± 8 hrs post procedure</time_frame>
    <description>Emboli in New Territory (ENT) is defined as embolization territories outside of the target downstream territory.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">183</enrollment>
  <condition>Stroke, Acute</condition>
  <arm_group>
    <arm_group_label>Acute Ischemic Stroke Patients</arm_group_label>
    <description>Acute Ischemic Stroke (AIS) patients treated with Medtronic Market-Released Neurothrombectomy Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neurothrombectomy</intervention_name>
    <description>Medtronic Market-Released Neurothrombectomy Device</description>
    <arm_group_label>Acute Ischemic Stroke Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        AIS patients treated with a Medtronic market-released neurothrombectomy device.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject/subject's legally authorized representative has given Informed Consent&#xD;
             according to country regulations, and/or EC requirements.&#xD;
&#xD;
          2. Subject has experienced an Acute Ischemic Stroke due to large intracranial vessel&#xD;
             occlusion in at least one of the following intracranial vessels: internal carotid&#xD;
             artery (ICA), M1 and M2 segments of the middle cerebral artery (MCA), basilar, and&#xD;
             vertebral arteries.&#xD;
&#xD;
          3. Subject has been or will be treated with a Medtronic market-released neurothrombectomy&#xD;
             device as the initial device used to remove the thrombus.&#xD;
&#xD;
          4. Subject is willing to participate in a 90-day follow-up visit.&#xD;
&#xD;
          5. Treatment within 8 hours of stroke symptom onset (defined as stroke onset to access&#xD;
             puncture).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Concurrent participation in another mechanical neurothrombectomy device trial or any&#xD;
        other clinical trial with an active treatment arm or where the study procedure or treatment&#xD;
        might confound the study analysis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ka Sing Lawrence Wong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Neuroscience Institute</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prasat Neurology Institute</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>108 Military Central Hospital</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bach Mai Hospital</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ho Chi Minh City Medicine and Pharmacy University</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The People's 115 Hospital</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
    <country>Thailand</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 1, 2017</study_first_submitted>
  <study_first_submitted_qc>December 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2017</study_first_posted>
  <results_first_submitted>July 2, 2020</results_first_submitted>
  <results_first_submitted_qc>August 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 19, 2020</results_first_posted>
  <last_update_submitted>August 7, 2020</last_update_submitted>
  <last_update_submitted_qc>August 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No individual participant data will be available.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT03364023/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acute Ischemic Stroke Patients</title>
          <description>Acute Ischemic Stroke (AIS) patients treated with Medtronic Market-Released Neurothrombectomy Device due to large intracranial vessel occlusion within 8 hours of symptom onset.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acute Ischemic Stroke Patients</title>
          <description>Acute Ischemic Stroke (AIS) patients treated with Medtronic Market-Released Neurothrombectomy Device due to large intracranial vessel occlusion within 8 hours of symptom onset.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="183"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.89" spread="13.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.13" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-stroke mRS</title>
          <description>The modified Rankin Scale (mRS) measures the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale ranges from 0-6, with lower values representing a better outcome.&#xD;
0-No symptoms at all&#xD;
No significant disability despite symptoms&#xD;
Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 3 Moderate disability; requiring some help 4 Moderately severe disability 5 Severe disability; bedridden, incontinent and requiring constant nursing care and attention 6 Dead</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>mRS = 0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                  </measurement_list>
                </category>
                <category>
                  <title>mRS = 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>mRS = 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>mRS = 3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>mRS = 4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>mRS = 5</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Done</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline NIHSS</title>
          <description>The NIHSS is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. NIHSS scores range from 0 - 42. A score of 0 indicates no stroke symptoms. Higher scores indicate incremental levels of neurological impairment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.20" spread="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Modified Rankin Scale (mRS) at 90 Days</title>
        <description>mRS is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke.&#xD;
0 No symptoms at all&#xD;
No significant disability despite symptoms; able to carry out all usual duties and activities&#xD;
Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance&#xD;
Moderate disability; requiring some help, but able to walk without assistance&#xD;
Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance&#xD;
Severe disability; bedridden, incontinent and requiring constant nursing care and attention&#xD;
Dead</description>
        <time_frame>90 Days Post Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acute Ischemic Stroke Patients</title>
            <description>Acute Ischemic Stroke (AIS) patients treated with Medtronic Market-Released Neurothrombectomy Device due to large intracranial vessel occlusion within 8 hours of symptom onset.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Rankin Scale (mRS) at 90 Days</title>
          <description>mRS is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke.&#xD;
0 No symptoms at all&#xD;
No significant disability despite symptoms; able to carry out all usual duties and activities&#xD;
Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance&#xD;
Moderate disability; requiring some help, but able to walk without assistance&#xD;
Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance&#xD;
Severe disability; bedridden, incontinent and requiring constant nursing care and attention&#xD;
Dead</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>mRS = 0-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mRS = 3-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Symptomatic Intracranial Hemorrhage (sICH) at 24 Hrs ± 8 Hrs Post Procedure</title>
        <description>Number of participants with symptomatic Intracranial hemorrhage (sICH) is defined as &gt;/= 4 points worsening from baseline on the National Institutes of Health Stroke Scale (NIHSS) associated with an image finding of intra-cranial hemorrhage (i.e., intracerebral or intraventricular) at 24 +/- 8 hrs post procedure.&#xD;
The NIHSS is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. NIHSS scores range from 0 - 42. A score of 0 indicates no stroke symptoms. Higher scores indicate incremental levels of neurological impairment.</description>
        <time_frame>24 hrs ± 8 hrs post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acute Ischemic Stroke Patients</title>
            <description>Acute Ischemic Stroke (AIS) patients treated with Medtronic Market-Released Neurothrombectomy Device due to large intracranial vessel occlusion within 8 hours of symptom onset.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Symptomatic Intracranial Hemorrhage (sICH) at 24 Hrs ± 8 Hrs Post Procedure</title>
          <description>Number of participants with symptomatic Intracranial hemorrhage (sICH) is defined as &gt;/= 4 points worsening from baseline on the National Institutes of Health Stroke Scale (NIHSS) associated with an image finding of intra-cranial hemorrhage (i.e., intracerebral or intraventricular) at 24 +/- 8 hrs post procedure.&#xD;
The NIHSS is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. NIHSS scores range from 0 - 42. A score of 0 indicates no stroke symptoms. Higher scores indicate incremental levels of neurological impairment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-Cause Mortality Through 90 Days Post Procedure</title>
        <description>Death through 90 days post procedure classified as neurological or non-neurological, with event leading to death.</description>
        <time_frame>90 Days Post Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acute Ischemic Stroke Patients</title>
            <description>Acute Ischemic Stroke (AIS) patients treated with Medtronic Market-Released Neurothrombectomy Device due to large intracranial vessel occlusion within 8 hours of symptom onset.</description>
          </group>
        </group_list>
        <measure>
          <title>All-Cause Mortality Through 90 Days Post Procedure</title>
          <description>Death through 90 days post procedure classified as neurological or non-neurological, with event leading to death.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Emboli in New Territory (ENT) at 24 Hrs ± 8 Hrs Post Procedure</title>
        <description>Emboli in New Territory (ENT) is defined as embolization territories outside of the target downstream territory.</description>
        <time_frame>24 hrs ± 8 hrs post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acute Ischemic Stroke Patients</title>
            <description>Acute Ischemic Stroke (AIS) patients treated with Medtronic Market-Released Neurothrombectomy Device due to large intracranial vessel occlusion within 8 hours of symptom onset.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Emboli in New Territory (ENT) at 24 Hrs ± 8 Hrs Post Procedure</title>
          <description>Emboli in New Territory (ENT) is defined as embolization territories outside of the target downstream territory.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected from the point of consent through 90 day follow up visit.</time_frame>
      <desc>For the purpose of this real-world registry, only the following Serious Adverse Events were collected:&#xD;
Symptomatic Intracranial Hemorrhage (sICH) at 24 ± 8 hrs post procedure&#xD;
Death through 90 days post procedure classified as neurological or non-neurological, with event leading to death&#xD;
Other [Not including Serious] Adverse Events were not monitored/assessed for this registry.</desc>
      <group_list>
        <group group_id="E1">
          <title>Acute Ischemic Stroke Patients</title>
          <description>Acute Ischemic Stroke (AIS) patients treated with Medtronic Market-Released Neurothrombectomy Device due to large intracranial vessel occlusion within 8 hours of symptom onset.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Symptomatic Intracranial Hemorrhage (sICH)</sub_title>
                <description>Symptomatic Intracranial Hemorrhage (sICH) at 24 ± 8 hrs post procedure</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medtronic Neurovascular Clinical Affairs</name_or_title>
      <organization>Medtronic Neurovascular Clinical Affairs</organization>
      <phone>9498373700</phone>
      <email>rs.nvclinicalprospr-sea@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

